Ogi Kwon, of R1 Revenue Cycle Management (RCM) offers insights on lessons learned from the COVID-19 pandemic and the future of price transparency.
The COVID-19 pandemic provides an opportunity for organizations to think about how they can be proactive and monitor new regulatory changes in real time, said Ogi Kwon, a manager in the regulatory team at R1 RCM's advisory and assurance department.
In this interview with Chief Healthcare Executive™, Kwon explains how he feels price transparency as a whole while be something that continues to be iterated upon going forward and how requirements could take different forms.
R1 RCM is a revenue cycle management company that offers technology-driven solutions to transform health care providers' patient experience and financial performance.
Breast cancer: Patients are told if they have dense breasts, but the conversation must continue
October 18th 2024A new FDA rule requires patients getting mammograms to be told if they have dense breasts. Arif Kamal of the American Cancer Society says providers should engage patients to talk about more screenings.